An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics

Area of Science:

• Pharmacology and Toxicology
• Mathematical Modeling
• Oncology

Background:

• Simultaneous pharmacokinetic-pharmacodynamic modeling is challenging, particularly linking drug concentrations to effects.
• Limited exposure variables exist to describe chemotherapy-induced hematotoxicity from circulating drug levels.
• Accurate assessment of drug exposure and toxicity is crucial for effective cancer treatment.

Purpose of the Study:

• To develop an interface model translating pharmacokinetic concentrations into pharmacodynamic exposure variables.
• To integrate this model into a complex system for analyzing chemotherapy-induced hematotoxicity.
• To assess the model's utility for dosage adjustment and sensitivity analysis in anticancer drug therapy.

Main Methods:

• Development of a nonlinear differential equation-based interface model with three parameters.
• Simulation studies to illustrate the model's relevance for dosage adjustment.
• Integration of the interface model with pharmacokinetic and pharmacodynamic models for docetaxel and cisplatin-induced neutropenia.

Main Results:

• The interface model successfully transforms pharmacokinetic concentrations into relevant exposure inputs for pharmacodynamic processes.
• Simulations demonstrated the model's utility in dosage adjustment strategies.
• The integrated system effectively analyzed the sensitivity of neutropenia to drug concentration variations.

Conclusions:

• The developed interface model provides a valuable tool for linking drug pharmacokinetics to pharmacodynamics, specifically for hematotoxicity.
• The integrated pharmacokinetic-pharmacodynamic-interface model system offers a robust platform for analyzing anticancer agent-induced hematotoxicity.
• This modeling approach can serve as a foundation for future enhancements incorporating novel experimental data.